PHERGain Phase 2 Trial: HER2-Positive Breast Cancer De-escalation and ctDNA Analyses

The 5-year results from the randomized phase 2 PHERGain trial demonstrate that tailoring chemotherapy in HER2-positive early breast cancer based on early PET scans maintains high invasive disease-free survival rates while allowing select patients to safely omit cytotoxic chemotherapy. Conducted across 45 European hospitals, the study evaluated a strategy-based de-escalation approach.

Patients Achieve 5-Year Outcomes Without Chemotherapy

• De-escalation Safety: Patients who responded early to targeted therapy (trastuzumab and pertuzumab) without chemotherapy achieved strong 5-year outcomes, sparing them from harsh cytotoxic side effects.
• PET-Guided Adaptation: 18F-FDG-PET scans performed after two treatment cycles successfully identified which patients could omit chemotherapy and which required it.
• Circulating Tumor DNA (ctDNA): Blood-based epigenetic assays showed strong potential for tracking tumor dynamics and clearance longitudinally without needing prior tumor tissue sequencing.

European Trial Protocol and 5-Year Survival Endpoints

As reported by nature.com, the PHERGain trial was prospectively registered at ClinicalTrials.gov under ID NCT03161353 before enrolling its first participant on June 26, 2017. Following the prespecified 3-year analysis, investigators amended the protocol in August 2022 to extend follow-up and evaluate long-term efficacy at 5 and 7 years post-surgery. The trial operated across 45 hospitals spanning Spain, France, Belgium, Germany, the United Kingdom, Italy, and Portugal.

The study randomized adult patients with operable HER2-positive invasive breast cancer into two primary groups. Group A received standard chemotherapy—comprising docetaxel and carboplatin—concurrently with dual HER2 blockade using trastuzumab and pertuzumab. Group B initiated therapy with only trastuzumab and pertuzumab (plus endocrine therapy if hormone receptor-positive). Patients in Group B who achieved a reduction in maximum standardized uptake value on an interim 18F-FDG-PET scan continued without chemotherapy, while non-responders switched to the standard chemotherapy regimen.

Trial Arm	Initial Treatment Strategy	Primary De-escalation Mechanism
Group A (n = 71)	Standard Chemotherapy + Dual HER2 Blockade	None (Fixed regimen across all cycles)
Group B (n = 285)	Dual HER2 Blockade Alone	18F-FDG-PET response-adapted

Exploratory ctDNA Analyses and Epigenetic Assays

Alongside long-term survival endpoints, the investigators integrated exploratory circulating tumor DNA (ctDNA) analyses using plasma samples collected at baseline, cycle 3 day 1 (C3D1), and prior to surgery. By analyzing plasma-derived cell-free DNA (cfDNA), the test identifies tumor-associated DNA methylation patterns without requiring prior sequencing of the patient’s primary tumor tissue.

Longitudinal tracking of ctDNA clearance provided critical biological insights into recurrence risks. While tissue-based markers remain the diagnostic cornerstone, non-invasive methylation classifiers offer a scalable method to monitor minimal residual disease. These exploratory assessments evaluated associations between ctDNA detection or clearance and subsequent surgical and 5-year outcomes.

Contraindications & When to Consult a Doctor

Key exclusions in the PHERGain trial protocol included patients with cT4 or cN3 disease, bilateral or clinically evident metastatic breast cancer, and significant cardiovascular disease with a left ventricular ejection fraction under 55%. Because trastuzumab and pertuzumab carry well-documented cardiac toxicities, baseline and regular cardiac monitoring are mandatory.

Evolving Standards in HER2-Positive Management

The 5-year data from the PHERGain trial mark a step forward in precision oncology, demonstrating that biomarker-driven de-escalation can successfully spare patients unnecessary toxicity without compromising long-term disease control. Future analyses scheduled at the 7-year mark will further solidify the long-term safety profile of omitting chemotherapy in metabolic responders.

More on Breast Cancer: Alcohol Consumption Directly Increases Breast Cancer Risk · UT San Antonio Chemist Develops "Smart Probe" to Illuminate Triple-Negative Breast Cancer Cells During Surgery · Dr. Mónica Hoffens Outlines Lifestyle Habits to Lower Breast Cancer Risk

References

• ClinicalTrials.gov. Study Record NCT03161353: PHERGain Trial Protocol. Available via ClinicalTrials.gov.
• nature.com. 5-year outcomes of chemotherapy de-escalation in HER2-positive early breast cancer and exploratory circulating tumor DNA analyses from the randomized phase 2 PHERGain trial.
• journals.viamedica.pl. Preoperative treatment of HER2-positive breast cancer. Oncology in Clinical Practice.